作者
Cher-Rin Chong, Wai Ping A Chan, Thanh H Nguyen, Saifei Liu, Nathan EK Procter, Doan T Ngo, Aaron L Sverdlov, Yuliy Y Chirkov, John D Horowitz
发表日期
2014/8
来源
Cardiovascular drugs and therapy
卷号
28
页码范围
347-360
出版商
Springer US
简介
The thioredoxin system, which consists of thioredoxin (Trx), nicotinamide adenine dinucleotide phosphate (NADPH) and thioredoxin reductase (TrxR), has emerged as a major anti-oxidant involved in the maintenance of cellular physiology and survival. Dysregulation in this system has been associated with metabolic, cardiovascular, and malignant disorders. Thioredoxin-interacting protein (TXNIP), also known as vitamin D-upregulated protein or thioredoxin-binding-protein-2, functions as a physiological inhibitor of Trx, and pathological suppression of Trx by TXNIP has been demonstrated in diabetes and cardiovascular diseases. Furthermore, TXNIP effects are partially Trx-independent; these include direct activation of inflammation and inhibition of glucose uptake. Many of the effects of TXNIP are initiated by its dissociation from intra-nuclear binding with Trx or other SH-containing proteins: these effects …
引用总数
20152016201720182019202020212022202320247715241310131348
学术搜索中的文章